best crypto for transactions, Featured snippets

SpaceX is valued at about $350 billion due to internal stock sales. According to an email sent to employees seen by the media, SpaceX and its investors have agreed to acquire the company's common stock of up to $1.25 billion at a price of $185 per share. This transaction values the rocket and satellite manufacturer owned by elon musk at about $350 billion.Expert: Central enterprises will continue to recruit in A-shares. On the evening of December 9, Huada Jiutian, a domestic EDA leader, announced that China Electronic Information Industry Group Co., Ltd. will become the actual controller of the company. So far, the number of A-share listed companies "incorporated" by central enterprises reached 10 in 2024. The end of 2024 is an important node for central enterprises to optimize the layout of listed platforms. The Work Plan for Improving the Quality of Listed Companies Controlled by Central Enterprises previously issued by the State-owned Assets Supervision and Administration Commission of the State Council made it clear that the adjustment and revitalization of the listing platform should be basically completed by the end of 2024, and it is supported to revitalize through absorption and merger, asset restructuring and cross-market operation, or to withdraw through free transfer and equity transfer, so as to further focus on the main business and advantageous areas. Looking forward to the next layout rhythm of central enterprises in the capital market, many experts interviewed by reporters believe that the pace of "recruiting" of central enterprises in A shares will continue. In the coming period, the cases of central enterprises strengthening their main business through capital operation and giving play to their strategic support and industrial leading functions will be on the rise. (shanghai securities news)Ministry of Finance of Korea: Korea's financial market is still facing uncertainty.

Russian Foreign Ministry Spokesperson Zacharova: The Russian Federation keeps in touch with all political forces in Syria. The Russian Federation is holding an operational headquarters meeting to discuss the security of Russians and Russian facilities in Syria.Argentine President Millai: Argentina's economy will grow in 2025 and inflation will decline.Policy combination boosts confidence, and public offering: China's assets will usher in a further increase in valuation. On December 9, the Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting to analyze and study the economic work in 2025. A number of public offerings said that the meeting sent a very positive signal. At present, the economy is resilient, the investor structure is constantly optimized, and the market activity continues to increase. China assets may have an opportunity to raise their valuations again. From the perspective of funds, Jing Shun Great Wall Fund analyzed that the current A-share market is in the most active stage since 2015, and there are many potential bulls in the market. Policy expectations are expected to drive incremental funds into the market, forming a resonance between emotions and funds. (SSE)

*ST Hanma: The reorganization plan of the company and its five subsidiaries was approved by the court. On December 11, 2024, the company and its five subsidiaries, Anhui Valin Automobile Co., Ltd., Anhui Xingma Special Purpose Vehicle Co., Ltd., Anhui Fuma Automobile Parts Group Co., Ltd., Anhui Fuma Electronic Technology Co., Ltd. and Wuhu Fuma Automobile Parts Co., Ltd., received the court ruling, approved their reorganization plans and terminated the reorganization procedures, and then entered the implementation stage.Ukrainian industrial sources: The attack on an oil depot in the Bryansk region of Russia did not affect the oil transportation to Europe via Ukraine.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.